"Effective connection and comprehensive development have been achieved in encouraging drug research and development innovation, ensuring production and supply, and promoting rational drug use." On November 1, the State Council Information Office held a series of press conferences with the theme of "The Start of the Talk from Authoritative Departments" to introduce Relevant information on "promoting high-quality development of health services and protecting people's health". Wang Bin, director of the General Office of the National Health Commission, said that during the "14th Five-Year Plan" period, relevant departments continued to improve the drug policy system and promote drug supply to ensure high-quality development.
First, comprehensively improve the level of institutionalization of national essential medicines. Revise and improve the catalog management methods, optimize the selection and adjustment procedures, dynamically adjust the national essential drugs catalog, and use institutional guarantees to adjust, highlighting the dominant position of essential drugs, continuing to improve the supply and quality of essential drugs, and promoting the priority distribution and use of essential drugs.
Secondly, improve the working mechanism to ensure supply and stable price of drugs in short supply. Focus on solving the urgent and anxious medication problems of the masses, give full play to the role of national and provincial-level linkage, strengthen coordinated monitoring, summary analysis, and hierarchical response of shortage drugs, and deepen the collaborative work pattern of departments.
Thirdly, consolidate and improve the supply guarantee mechanism for children’s drugs and generic drugs. Highlight the clinical value and clinical demand orientation of drugs, and update the list of children's drugs that encourage research and development applications. Multiple batches have been updated so far, and drugs on the list will be reviewed and approved with priority. At the same time, a catalog of encouraged generic drugs has been formulated to guide enterprises in research and development and production by increasing scientific research support, giving priority to review and approval, and giving priority to inclusion in the medical insurance reimbursement catalog.
In addition, medical institutions continue to improve their pharmaceutical service capabilities, strengthen national and provincial drug use monitoring, improve drug clinical comprehensive evaluation mechanisms and technical specification applications, further strengthen analysis, monitoring and evaluation results application, and further improve basic basic skills through these comprehensive measures. Level of drug institutionalization.
微信扫一扫打赏
